Irving-based Caris Life Sciences, Inc., announced that they have completed the sale of CLS’ anatomic pathology business to Miraca Holdings Inc., Japan’s largest clinical and laboratory testing service provider. As listed under the terms of the transaction, Miraca has acquired the anatomic pathology business operated by Caris Diagnostics, Inc. and its subsidiaries and affiliates. The total purchase price was $725 million, including the repayment of the existing debt, subject to customary post-closing price adjustments.

Print Friendly